At a glance
- Originator Almirall-Prodesfarma
- Developer Almirall S.A.
- Class Anti-inflammatories; Non-opioid analgesics; Oxazoles; Small molecules
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis; Pain
Most Recent Events
- 20 Jun 2003 Phase-II/III clinical trials in Osteoarthritis in Spain (PO)
- 20 Jun 2003 Phase-II/III clinical trials in Osteoarthritis in USA (PO)
- 20 Jun 2003 Data presented at the 4th Annual European Congress of Rheumatology (EULAR-2003) have been added to the pharmacokinetics, adverse events and Rheumatic disease pharmacodynamics sections